REVA Medical, Inc. (RVA) will present new data on the Fantom bioresorbable scaffold from its pilot study in patients with a specific type of heart attack called ST-segment elevated myocardial infarction. Patients experiencing heart attacks account for 30 to 40% of the percutaneous coronary intervention (PCI) patient population, and PCI is performed to restore blood flow to the heart. While these patients are at a higher risk than stable patients, the characteristics of their arterial lesions are typically well suited to bioresorbable scaffolds
